Publikationen von A. Ullrich

Ferby, I.; Reschke, M.; Kudlacek, O.; Knyazev, P.; Pante, G.; Amann, K.; Sommergruber, W.; Kraut, N.; Ullrich, A.; Fässler, R. et al.; Klein, R.: Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation. Nature Medicine 12 (5), S. 568 - 573 (2006)

Sukocheva, O.; Wadham, C.; Holmes, A.; Albanese, N.; Verrier, E.; Feng, F.; Bernal, A.; Derian, C. K.; Ullrich, A.; Vadas, M. A. et al.; Xia, P.: Estrogen transactivates EGFR via the sphingosine 1-phosphate receptor Edg-3: the role of sphingosine kinase-1. Journal of Cell Biology 173 (2), S. 301 - 310 (2006)

Vajkoczy, P.; Knyazev, P.; Kunkel, A.; Capelle, H. H.; Behrndt, S.; von Tengg-Kobligk, H.; Kiessling, F.; Eichelsbacher, U.; Essig, M.; Read, T. A. et al.; Erber, R.; Ullrich, A.: Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. Proceedings of the National Academy of Sciences of the United States of America 103 (15), S. 5799 - 5804 (2006)

Strebhardt, K.; Ullrich, A.: Targeting polo-like kinase 1 for cancer therapy. Nature Reviews Cancer 6 (4), S. 321 - 330 (2006)

Erber, R.; Eichelsbacher, U.; Powajbo, V.; Korn, T.; Djonov, V.; Lin, J. H.; Hammes, H. P.; Grobholz, R.; Ullrich, A.; Vajkoczy, P.: EphB4 controls blood vascular morphogenesis during postnatal angiogenesis. EMBO Journal 25 (3), S. 628 - 641 (2006)

Sasaki, T.; Knyazev, P. G.; Clout, N. J.; Cheburkin, Y.; Göhring, W.; Ullrich, A.; Timpl, R.; Hohenester, E.: Structural basis for Gas6-Axl signalling. EMBO Journal 25 (1), S. 80 - 87 (2006)

Fischer, O. M.; Hart, S.; Ullrich, A.: Dissecting the epidermal growth factor receptor signal transactivation pathway. Methods in Molecular Biology 327, S. 85 - 97 (2006)

Jiang, L. Q.; Feng, X.; Zhou, W.; Knyazev, P. G.; Ullrich, A.; Chen, Z.: Csk-Binding Protein (Cbp) Negatively Regulates Epidermal Growth Factor-Induced Cell Transformation by Controlling Src Activation. Oncogene 40, S. 5495 - 5506 (2006)

Keri, G.; Orfi, L.; Eros, D.; Hegymegi-Barakonyi, B.; Szantai-Kis, C.; Horvath, Z.; Waczek, F.; Marosfalvi, J.; Szabadkai, I.; Pato, J. et al.; Greff, Z.; Hafenbradl, D.; Daub, H.; Muller, G.; Klebl, B.; Ullrich, A.: Signal transduction therapy with rationally designed kinase inhibitors. Current Signal Transduction Therapy 1 (1), S. 67 - 95 (2006)

Szantai-Kis, C.; Kovesdi, I.; Eros, D.; Banhegyi, P.; Ullrich, A.; Keri, G.; Orfi, L.: Prediction oriented QSAR modelling of EGFR inhibition. Current Medicinal Chemistry 13 (3), S. 277 - 287 (2006)

Abraham, R.; Schafer, J.; Rothe, M.; Bange, J.; Knyazev, P.; Ullrich, A.: Identification of MMP-15 as an anti-apoptotic factor in cancer cells. Journal of Biological Chemistry 280 (40), S. 34123 - 34132 (2005)

Hart, S.; Fischer, O. M.; Prenzel, N.; Zwick-Wallasch, E.; Schneider, M.; Hennighausen, L.; Ullrich, A.: GPCR-induced migration of breast carcinoma cells depends on both EGFR signal transactivation and EGFR-independent pathways. Biological Chemistry 386 (9), S. 845 - 855 (2005)

Godl, K.; Gruss, O. J.; Eickhoff, J.; Wissing, J.; Blencke, S.; Weber, M.; Degen, H.; Brehmer, D.; Orfi, L.; Horvath, Z. et al.; Keri, G.; Muller, S.; Cotten, M.; Ullrich, A.; Daub, H.: Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling. Cancer Research 65 (15), S. 6919 - 6926 (2005)

Vajkoczy, P.; Kunkel, A.; Erber, R.; Capelle, H.; Eichelsbacher, U.; Ullrich, A.: Dominant-negative inhibition of the receptor tyrosine kinase receptor AXL suppresses glioma cell migration and invasion and prolongs survival. Neuro-Oncology 7 (3), S. 354 - 354 (2005)

van der Horst, E. H.; Murgia, M.; Treder, M.; Ullrich, A.: Anti-HER-3 MAbs inhibit HER-3-mediated signaling in breast cancer cell lines resistant to anti-HER-2 antibodies. International Journal of Cancer 115 (4), S. 519 - 527 (2005)

Berger, I. R.; Buschbeck, M.; Bange, J.; Ullrich, A.: Identification of a transcriptionally active hVH-5 pseudogene on 10q22-2. Cancer Genetics and Cytogenetics 159 (2), S. 155 - 159 (2005)

Fuchs, M.; Hermannstadter, C.; Specht, K.; Knyazev, P.; Ullrich, A.; Rosivatz, E.; Busch, R.; Hutzler, P.; Hofler, H.; Luber, B.: Effect of tumor-associated mutant E-cadherin variants with defects in exons 8 or 9 on matrix metalloproteinase 3. Journal of Cellular Physiology 202 (3), S. 805 - 813 (2005)

van der Horst, E. H.; Weber, I.; Ullrich, A.: Tyrosine phosphorylation of PYK2 mediates heregulin-induced glioma invasion: Novel heregulin/HER3-stimulated signaling pathway in glioma. International Journal of Cancer 113 (5), S. 689 - 698 (2005)

Farhadi, M. R.; Capelle, H. H.; Erber, R.; Ullrich, A.; Vajkoczy, P.: Combined inhibition of vascular endothelial growth factor and platelet-derived growth factor signaling: effects on the angiogenesis, microcirculation, and growth of orthotopic malignant gliomas. Journal of Neurosurgery 102 (2), S. 363 - 370 (2005)

Buschbeck, M.; Ullrich, A.: The unique C-terminal tail of the mitogen-activated protein kinase ERK5 regulates its activation and nuclear shuttling. Journal of Biological Chemistry 280 (4), S. 2659 - 2667 (2005)